Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 237

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Action of Atorvastatin in Combined Hyperlipidemia: Preferential Reduction of Cholesteryl Ester Transfer From HDL to VLDL1 Particles

Guerin, Maryse, Lassel, Taous S., Le Goff, Wilfried, Farnier, Michel, Chapman, M. John · 2000 · Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

Abstract —Combined hyperlipidemia (CHL) is characterized by a concomitant elevation of plasma levels of triglyceride-rich, very low density lipoproteins (VLDLs) and cholesterol-rich, low density lipoproteins (LDLs). The predominance of small, dense LDLs contributes significantly to the premature development of coronary artery disease in patients with this atherogenic dyslipoproteinemia. In the present study, we evaluated the impact of atorvastatin, a newly developed inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, on the cholesteryl ester transfer protein (CETP)–mediated remodeling of apolipoprotein (apo) B–containing lipoprotein subspecies, and more specifically, the particle subpopulations of VLDL and LDL in CHL. In parallel, we evaluated the atorvastatin-induced modulation of the quantitative and qualitative features of atherogenic apo B–containing and cardioprotective apo AI–containing lipoprotein subspecies. Atorvastatin therapy (10 mg/d for a 6-week period) in patients with a lipid phenotype typical of CHL (n=18) induced reductions of 31% ( P <0.0001) and 36% ( P <0.0001) in plasma total cholesterol and LDL cholesterol, respectively. In addition, atorvastatin significantly reduced VLDL cholesterol, triglycerides, and apo B levels by 43% ( P <0.0001), 27% ( P =0.0006), and 31% ( P <0.0001), respectively. The plasma concentrations of triglyceride-rich lipoproteins (VLDL1, Sf 60 to 400; VLDL2, Sf 20 to 60; and intermediate density lipoproteins, Sf 12 to 20) and of LDL, as determined by chemical analysis, were markedly diminished after drug therapy (−30% and −28%, respectively; P <0.0007). Atorvastatin significantly reduced circulating levels of all major LDL subspecies, ie, light (−28%, P <0.0008), intermediate (−27%, P <0.0008), and dense (−32%, P <0.0008) LDL; moreover, in terms of absolute lipoprotein mass, the reduction in dense LDL levels (mean −62 mg/dL) was preponderant. In addition, the reduction in plasma dense LDL concentration after therapy was significantly correlated with a reduction in plasma VLDL1 levels ( r =0.429, P =0.0218). Atorvastatin induced a significant reduction (−7%, P =0.0039) in total CETP-dependent CET activity, which accurately reflects a reduction in plasma CETP mass concentration. Total CETP-mediated CET from high density lipoproteins to apo B–containing lipoproteins was significantly reduced (−26%, P <0.0001) with drug therapy. Furthermore, CETP activity was significantly correlated with the atorvastatin-induced reduction in plasma VLDL1 levels ( r =0.456, P =0.0138). Indeed, atorvastatin significantly and preferentially decreased CET from HDL to the VLDL1 subfraction (−37%, P =0.0064), thereby reducing both the levels (−37%, P =0.0001) and the CE content (−20%, P <0.005) of VLDL1. We interpret our data to indicate that 2 independent but complementary mechanisms may be operative in the atorvastatin-induced reduction of atherogenic LDL levels in CHL: first, a significant degree of normalization of both the circulating levels and the quality of their key precursors, ie, VLDL1, and second, enhanced catabolism of the major LDL particle subclasses (ie, light, intermediate, and dense LDL) due to upregulation of hepatic LDL receptors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.atv.20.1.189

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 237

Metadata

Authors
Guerin, M., Lassel, T. S., Le Goff, W., Farnier, M., & Chapman, M. J.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2000-01
Volume
20
Issue
1
Pages
189-197
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
OpenAlex
W2164941554
Cited by
237
References
2
FWCI
21.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Action of Atorvastatin in Combined Hyperlipidemia: Preferential Reduction of Cholesteryl Ester Transfer From HDL to VLDL1 Particles. https://app.cochat.ai/papers/10.1161/01.atv.20.1.189
The paper
Guerin, M., Lassel, T. S., Le Goff, W., Farnier, M., & Chapman, M. J. (2000). Action of Atorvastatin in Combined Hyperlipidemia: Preferential Reduction of Cholesteryl Ester Transfer From HDL to VLDL1 Particles. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.20.1.189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.